BIOLIFE SOLUTIONS Business Summary

BioLife Solutions Inc. (BLFS) operates as a specialized provider of cell processing tools and services, primarily serving the cell and gene therapy (CGT) market. Following the strategic divestiture of its non-core cold chain and freezer business lines in late 2025, the company has transitioned into a high-margin, pure-play cell processing entity. Its revenue model is driven by recurring sales of proprietary biopreservation consumables, most notably its CryoStor® and HypoThermosol® media, which are embedded in over 250 clinical trials and 16 commercially approved therapies. The company’s primary business segment, Cell Processing, focuses on maximizing the viability and health of biologic materials during manufacturing and distribution. Within the competitive landscape, BioLife competes with diversified life science giants and specialized providers such as Lonza Group, Azenta (formerly Brooks Automation), and Charles River Laboratories. BioLife distinguishes itself as the dominant pure-play leader in the biopreservation media niche, maintaining a significant market share due to its products' critical role in regulatory-approved manufacturing protocols. Roderick de Greef leads the company as Chairman and CEO, bringing over 20 years of experience as a CFO and COO within the life sciences sector. The executive team includes Executive Vice President and Chief Scientific Officer Dr. Aby J. Mathew, a foundational member of the scientific team who co-developed the company’s core biopreservation platforms, and Chief Technology Officer Dr. Sean Werner, who oversees technical innovation. The leadership is further supported by CFO Troy Wichterman and Chief Commercial Officer Todd Berard. BioLife’s board of directors features prominent industry figures, including Tony J. Hunt, Executive Chairman of Repligen, and Joydeep Goswami, a senior executive at Illumina. The company maintains a strong institutional investor base, with Casdin Capital, BlackRock, and Vanguard Group holding significant positions, reflecting confidence in its streamlined focus on the high-growth regenerative medicine supply chain.